Kenneth Smith

Spark Therapeutics generated revenues of $25.18 million in the second quarter of 2018 compared to $1.48 million in Q2 2017.

AbbVie (ABBV) generated net revenue of $7.9 billion in 1Q18 compared to $6.5 billion in 1Q17.

Spark Therapeutics’ (ONCE) operating expenses decreased from $78.48 million in Q2 2017 to $59.78 million in Q2 2018.

Sucampo Pharmaceuticals (SCMP) recently completed a Phase 3 study for the alternate sprinkle formulation of Amitiza (lubiprostone) in adults with CIC (chronic idiopathic constipation).

Ignyta (RXDX) has completed enrollment for a Phase 1 clinical trial of RXDX-105, an orally bioavailable small molecule tyrosine kinase inhibitor.

Ignyta’s (RXDX) R&D (research and development) expenses increased from $16.6 million in 3Q16 to $21.7 million in 3Q17, a 30% rise.

In October 2017, Ignyta (RXDX) raised $150 million by issuing 10 million shares of its common stock.

In fiscal 2018 and fiscal 2019, Thermo Fisher Scientific (TMO) is expected to generate revenue of $24.08 billion and $25.19 billion, respectively, compared with revenue of $20.92 billion in fiscal 2017.

Illumina’s cost of product revenue increased from $173.0 million in the third quarter of 2017 to $184.0 million in the third quarter of 2018.

Nektar Therapeutics generated total revenues of $27.76 million in the third quarter of 2018 as compared with $152.93 million in the third quarter of 2017.

In November 2018, of the total 18 analysts covering Alexion Pharmaceuticals (ALXN), 16 analysts have given the stock a “buy” or higher rating, and two analysts have given it a “hold” rating.

In November, six analysts recommended a “strong buy,” ten recommended a “buy,” and 12 recommended a “hold” for Gilead Sciences.

Of the total 28 analysts covering Stryker (SYK) in October 2018, 19 analysts have given the stock a “buy” or higher rating, and nine analysts have given Stryker a “hold” rating.

In September, of the seven analysts covering ViewRay (VRAY), six have given its stock “buy” or higher ratings, and one analyst has given it a “sell” rating.

Agilent Technologies’ (A) Life Sciences and Applied Markets segment had revenues of $510 million in Q3 2017 compared to $540 million in Q3 2018.

Agilent Technologies (A) has been on an acquisition spree in 2018 with major acquisitions made until the third quarter.

Eli Lilly (LLY) is expected to post revenues of $24.33 billion in fiscal 2018 and $24.8 billion in fiscal 2019.

Thermo Fisher Scientific (TMO) operates in four business segments.

Brilinta’s sales increased by 13.0% to $316.0 million, and Farxiga’s sales grew 34.0% to $340.0 million in the second quarter.

Revenues from the Oncology Systems segment increased from $564.4 million in fiscal Q3 2017 to $667.2 million in fiscal Q3 2018.

Baxter International’s (BAX) global business units delivered strong performances in the second quarter.

Tesaro stock has been on a downward trajectory for the past 52 weeks. From a high of $135 on September 5, 2017, it has corrected to $27 in August.

Under its immunology program, Nektar Therapeutics (NKTR) is developing NKTR-358 in collaboration with Eli Lilly and Company (LLY).

Acadia Pharmaceuticals’ Nuplazid is commercialized in the US market for the treatment of hallucinations and delusions related to Parkinson’s disease psychosis.

T:sport is Tandem’s next-generation hardware platform, which is expected to reduce the size of the t:slim pump by 50%.

Boston Scientific’s (BSX) Cardiovascular segment’s net sales increased from $851 million in Q1 2017 to $933 million in Q1 2018.

Worldwide revenues of Boston Scientific’s (BSX) electrophysiology business grew 20% from $64 million in Q1 2017 to $75 million in Q1 2018.

Sales from Baxter International’s (BAX) Acute Therapies rose 22%, from $106 million in Q1 2017 to $129 million in Q1 2018.

Editas Medicine’s core capability in genome editing makes use of CRISPR technology to create molecules that can specifically edit DNA.

Between 1Q17 and 1Q18, Johnson & Johnson’s (JNJ) infectious disease product sales rose 10.8% from $749 million to $830 million.

In 1Q18, Johnson & Johnson (JNJ) generated revenue of $20 billion, compared with $17.7 billion in 1Q17.

Johnson & Johnson (JNJ) derives revenue from four regions: the United States, Europe, the Western Hemisphere excluding the United States, and the Asia-Pacific region and Africa.

According to Amicus Therapeutics, the annual incidence of the disease in newborn males is estimated to be between 1:40,000 and 1:60,000.

Of the 20 analysts covering Spark Therapeutics in April 2018, four have given the stock “strong buy” recommendations.

Amgen (AMGN) is one of the world’s leading biotechnology companies, with a presence in ~100 countries.

Apart from Roxadustat, other products in FibroGen’s pipeline include Pamrevlumab (or FG-3019) and FG-5200.

In 2018, LHC Group is expected to report revenue of $1.2 billion. What about its peers?

To better position itself and compete effectively in this evolving healthcare environment, Tenet Healthcare has taken a number of steps.

Masimo’s future growth strategy is focused on international expansion opportunities in Europe, Asia, Asia-Pacific, the Middle East, and Latin America.

Depomed (DEPO) has adopted a three-pronged business strategy with three key elements: maintain, build, and grow.

AmerisourceBergen’s (ABC) operations are organized based on the products and services it provides to customers.

Boston Scientific (BSX) operates in three business segments that cater to seven different product categories.

Integer Holdings Corporation provides custom battery packs to energy, military, and environmental markets for use in extreme environments.

Edwards Lifesciences’ (EW) products can be categorized into three therapeutic areas: transcatheter heart valve, surgical heart valve, and critical care.

Between November 22 and February 21, Universal Health Services stock has risen 19% to reach $117.

Alkermes’ ALKS3831 is an investigational oral medicine is targeted for the treatment of schizophrenia.

Vanda Pharmaceuticals’ (VNDA) Hetlioz was approved by the FDA in January 2014 for the treatment of Non-24-Hour Sleep Wake Disorder.

Regeneron Pharmaceuticals (REGN) currently has 15 products in clinical development.

In January 2017, Regeneron Pharmaceuticals’ (REGN) Kevzara was approved in Canada for the treatment of patients with active rheumatoid arthritis.

NxStage Medical (NXTM) generated revenue of $393.9 million in 2017 compared to $366.3 million in 2016.